Based on the potential immunomodulatory activity of HDAC inhibition, this clinical trial tested the combination of a pan HDAC inhibitor with the PD‐1 inhibitor pembrolizumab in treatment‐naïve and treatment‐resistant patients with UC or RCC, and then it expanded also to PCA pts. Here, HDAC9 is linked to renal cell carcinoma.